The global Age-Related Macular Degeneration (AMD) Market is experiencing robust growth, reflecting the urgent need for effective treatments and the expanding patient demographic. Valued at approximately $10.3 billion in 2023, the market is projected to reach an impressive $20.1 billion by 2032, demonstrating a healthy Compound Annual Growth Rate (CAGR) of around 7.5% over the forecast period. This strong growth is a testament to the significant investment in research and development, particularly for novel therapies that address the long-standing unmet needs in dry AMD. The market is propelled by a combination of factors, including the increasing number of individuals over the age of 60, who are most susceptible to the disease, and a greater awareness among both patients and healthcare providers about the importance of early detection and treatment. While the market for wet AMD treatments, particularly anti-VEGF therapies, remains the dominant segment, the fastest growth is expected to come from the pipeline of new drugs and therapies targeting dry AMD. The financial opportunity within this market is substantial, drawing in a wide range of players from large pharmaceutical corporations to specialized biotech firms. As new therapies gain regulatory approval and hit the market, the size and scope of this opportunity are expected to expand further, reshaping the landscape of ophthalmic care. For a deeper understanding of these market dynamics and future projections, a comprehensive analysis is available in the full Age-Related Macular Degeneration Market report.